Fundraising FoxPredxbio
Pittsburgh, US · Founded 2017 · 5 known investors
Find your way into Predxbio
Sign up to see every warm intro you have to Predxbio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Predxbio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PredxBio develops tissue analysis software that uses spatial multi-omics data to identify biomarkers and inform drug development decisions. The platform helps pharmaceutical and biotech companies move from exploratory tissue analysis to clinical development with explainable insights about cell states, microenvironments, and therapeutic response patterns.
Founders & leadership
Predxbio was founded in 2017 by S. Chakra Chennubhotla, D. Lansing Taylor, Michael J. Becich, and Jeffrey L. Fine.
SC
DL
D. Lansing TaylorCo-founder, Scientific & Business AdvisorDr. Taylor has held academic positions at Harvard, Carnegie Mellon University, and the University of Pittsburgh, and has founded or led multiple biotechnology companies including Cellomics, Cellumen, Cernostics, and Biosystics. His expertise spans quantitative systems pharmacology, patient-derived cellular models, and spatial omics approaches applied to drug discovery in liver disease and oncology.
JL
Jeffrey L. FineCo-founder, Scientific AdvisorJeffrey L. Fine is co-founder and scientific advisor at PredxBio. He has expertise in explainable AI, pathology informatics, surgical pathology, and breast and gynecological cancer research.
BD
B. Dusty MajumdarChief Executive OfficerB. Dusty Majumdar is Chief Executive Officer of PredxBio, a spatial biology platform company. Previously, he held commercial and product leadership roles at IBM Watson Health, GE HealthCare, Exact Sciences, and ASCO, with experience across AI-enabled health platforms, precision oncology, medical imaging, and genomics.
B
BruceVP Software EngineeringBruce holds a background in quantitative systems pharmacology and computational pathology, with prior academic roles at Harvard, Carnegie Mellon University, and the University of Pittsburgh, as well as experience founding and leading biotechnology companies including Cellomics, Cellumen, Cernostics, and Biosystics. He is VP of Software Engineering at PredxBio, which develops tissue analysis software using spatial multi-omics data to identify biomarkers for drug development.
Board
WN
Investors · 5
Central Texas Angel Networklisted by Central Texas Angel NetworkAustin
How we know: Central Texas Angel Network's portfolio page · Not right? Tell us
Emerging Ventureslisted by Emerging VenturesLos Angeles · $100K – $500K
How we know: Emerging Ventures's portfolio page · Not right? Tell us
Keiretsu Forumlisted by Keiretsu ForumSan Francisco East Bay · $250K – $2M
How we know: Keiretsu Forum's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$2M disclosed across 5 rounds · 2018–2023
▶$601.3KraisedAug 2023 · 11 investors · Other Health CareRule 506(b)
▶$601.3KraisedAug 2023 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stanley MarksDirector
- Srinivas Chakra ChennubhotlaExecutive Officer, Director
- William NewlinDirector
- B. Dusty MajumdarExecutive Officer, Director
- D. Lansing TaylorDirector
- Offering amount
- $4M
- Amount sold
- $601.3K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$260KraisedFeb 2021 · 4 investors · Other Health CareRule 506(b)
▶$260KraisedFeb 2021 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- D. Lansing TaylorExecutive Officer, Director
- S. Chakra ChennubhotlaExecutive Officer, Director
- William NewlinDirector
- Offering amount
- $350K
- Amount sold
- $260K
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$463.3KraisedAug 2020 · 7 investors · Other Health CareRule 506(b)
▶$463.3KraisedAug 2020 · 7 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- William NewlinDirector
- D. Lansing TaylorExecutive Officer, Director
- S. Chakra ChennubhotlaExecutive Officer, Director
- Offering amount
- $463.3K
- Amount sold
- $463.3K
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$275KraisedAug 2019 · 4 investors · Other Health CareRule 506(b)
▶$275KraisedAug 2019 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- D. Lansing TaylorExecutive Officer, Director
- William NewlinDirector
- S. Chakra ChennubhotlaExecutive Officer, Director
- Offering amount
- $400K
- Amount sold
- $275K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$400KraisedSep 2018 · 6 investors · Other Health CareRule 506(b)
▶$400KraisedSep 2018 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- William NewlinDirector
- D. Lansing TaylorExecutive Officer, Director
- S. Chakra ChennubhotlaExecutive Officer, Director
- Offering amount
- $400K
- Amount sold
- $400K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase I | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Predxbio do?
- PredxBio develops tissue analysis software that uses spatial multi-omics data to identify biomarkers and inform drug development decisions. The platform helps pharmaceutical and biotech companies move from exploratory tissue analysis to clinical development with explainable insights about cell states, microenvironments, and therapeutic response patterns.
- Who founded Predxbio?
- Predxbio was founded by S. Chakra Chennubhotla, D. Lansing Taylor, Michael J. Becich, Jeffrey L. Fine in 2017.
- Who are Predxbio's investors?
- Predxbio's investors include Central Texas Angel Network, Emerging Ventures, Keiretsu Forum, Newlin Investment Company LLC, NW Angel.
- How much funding has Predxbio raised?
- Predxbio has disclosed $2M raised across 5 rounds.
- Where is Predxbio headquartered?
- Predxbio is headquartered in Pittsburgh, US.